Literature DB >> 21947280

Osteoclast progenitors reside in the peroxisome proliferator-activated receptor γ-expressing bone marrow cell population.

Wei Wei1, Daniel Zeve, Xueqian Wang, Yang Du, Wei Tang, Paul C Dechow, Jonathan M Graff, Yihong Wan.   

Abstract

Osteoclasts are bone-resorbing cells essential for skeletal development, homeostasis, and regeneration. They derive from hematopoietic progenitors in the monocyte/macrophage lineage and differentiate in response to RANKL. However, the precise nature of osteoclast progenitors is a longstanding and important question. Using inducible peroxisome proliferator-activated receptor γ (PPARγ)-tTA TRE-GFP (green fluorescent protein) reporter mice, we show that osteoclast progenitors reside specifically in the PPARγ-expressing hematopoietic bone marrow population and identify the quiescent PPARγ(+) cells as osteoclast progenitors. Importantly, two PPARγ-tTA TRE-Cre-controlled genetic models provide compelling functional evidence. First, Notch activation in PPARγ(+) cells causes high bone mass due to impaired osteoclast precursor proliferation. Second, selective ablation of PPARγ(+) cells by diphtheria toxin also causes high bone mass due to decreased osteoclast numbers. Furthermore, PPARγ(+) cells respond to both pathological and pharmacological resorption-enhancing stimuli. Mechanistically, PPARγ promotes osteoclast progenitors by activating GATA2 transcription. These findings not only identify the long-sought-after osteoclast progenitors but also establish unprecedented tools for their visualization, isolation, characterization, and genetic manipulation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947280      PMCID: PMC3232921          DOI: 10.1128/MCB.05979-11

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  61 in total

1.  PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro.

Authors:  E D Rosen; P Sarraf; A E Troy; G Bradwin; K Moore; D S Milstone; B M Spiegelman; R M Mortensen
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

2.  PPAR gamma is required for placental, cardiac, and adipose tissue development.

Authors:  Y Barak; M C Nelson; E S Ong; Y Z Jones; P Ruiz-Lozano; K R Chien; A Koder; R M Evans
Journal:  Mol Cell       Date:  1999-10       Impact factor: 17.970

3.  Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line.

Authors:  R Constien; A Forde; B Liliensiek; H J Gröne; P Nawroth; G Hämmerling; B Arnold
Journal:  Genesis       Date:  2001-05       Impact factor: 2.487

Review 4.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

5.  Conditional gene targeting in macrophages and granulocytes using LysMcre mice.

Authors:  B E Clausen; C Burkhardt; W Reith; R Renkawitz; I Förster
Journal:  Transgenic Res       Date:  1999-08       Impact factor: 2.788

6.  Sequential requirements for SCL/tal-1, GATA-2, macrophage colony-stimulating factor, and osteoclast differentiation factor/osteoprotegerin ligand in osteoclast development.

Authors:  T Yamane; T Kunisada; H Yamazaki; T Nakano; S H Orkin; S I Hayashi
Journal:  Exp Hematol       Date:  2000-07       Impact factor: 3.084

7.  Cloning and characterization of a novel mouse Siglec, mSiglec-F: differential evolution of the mouse and human (CD33) Siglec-3-related gene clusters.

Authors:  T Angata; R Hingorani; N M Varki; A Varki
Journal:  J Biol Chem       Date:  2001-09-28       Impact factor: 5.157

8.  Identification of multiple osteoclast precursor populations in murine bone marrow.

Authors:  Claire Jacquin; Diane E Gran; Sun Kyeong Lee; Joseph A Lorenzo; Hector L Aguila
Journal:  J Bone Miner Res       Date:  2005-10-18       Impact factor: 6.741

9.  Preadipocyte conversion to macrophage. Evidence of plasticity.

Authors:  Guillaume Charrière; Béatrice Cousin; Emmanuelle Arnaud; Mireille André; Francis Bacou; Luc Penicaud; Louis Casteilla
Journal:  J Biol Chem       Date:  2003-01-07       Impact factor: 5.157

10.  Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors.

Authors:  F Arai; T Miyamoto; O Ohneda; T Inada; T Sudo; K Brasel; T Miyata; D M Anderson; T Suda
Journal:  J Exp Med       Date:  1999-12-20       Impact factor: 14.307

View more
  30 in total

1.  Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ.

Authors:  Wei Wei; Paul A Dutchak; Xunde Wang; Xunshan Ding; Xueqian Wang; Angie L Bookout; Regina Goetz; Moosa Mohammadi; Robert D Gerard; Paul C Dechow; David J Mangelsdorf; Steven A Kliewer; Yihong Wan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

Review 2.  Minireview: nuclear receptor regulation of osteoclast and bone remodeling.

Authors:  Zixue Jin; Xiaoxiao Li; Yihong Wan
Journal:  Mol Endocrinol       Date:  2014-12-30

3.  Loss of the Hematopoietic Stem Cell Factor GATA2 in the Osteogenic Lineage Impairs Trabecularization and Mechanical Strength of Bone.

Authors:  Alexander Tolkachov; Cornelius Fischer; Thomas H Ambrosi; Melissa Bothe; Chung-Ting Han; Matthias Muenzner; Susanne Mathia; Marjo Salminen; Georg Seifert; Mario Thiele; Georg N Duda; Sebastiaan H Meijsing; Sascha Sauer; Tim J Schulz; Michael Schupp
Journal:  Mol Cell Biol       Date:  2018-05-29       Impact factor: 4.272

4.  Cthrc1 controls adipose tissue formation, body composition, and physical activity.

Authors:  J Patrizia Stohn; Qiaozeng Wang; Matthew E Siviski; Kevin Kennedy; Yong-Ri Jin; Doreen Kacer; Victoria DeMambro; Lucy Liaw; Calvin P Vary; Clifford J Rosen; Igor Prudovsky; Volkhard Lindner
Journal:  Obesity (Silver Spring)       Date:  2015-07-07       Impact factor: 5.002

5.  Lentiviral delivery of PPARγ shRNA alters the balance of osteogenesis and adipogenesis, improving bone microarchitecture.

Authors:  Aaron W James; Jia Shen; Kevork Khadarian; Shen Pang; Greg Chung; Raghav Goyal; Greg Asatrian; Omar Velasco; Jung Kim; Xinli Zhang; Kang Ting; Chia Soo
Journal:  Tissue Eng Part A       Date:  2014-07-29       Impact factor: 3.845

6.  Orexin regulates bone remodeling via a dominant positive central action and a subordinate negative peripheral action.

Authors:  Wei Wei; Toshiyuki Motoike; Jing Y Krzeszinski; Zixue Jin; Xian-Jin Xie; Paul C Dechow; Masashi Yanagisawa; Yihong Wan
Journal:  Cell Metab       Date:  2014-05-01       Impact factor: 27.287

Review 7.  The multi-faceted role of retinoid X receptor in bone remodeling.

Authors:  María P Menéndez-Gutiérrez; Mercedes Ricote
Journal:  Cell Mol Life Sci       Date:  2017-01-19       Impact factor: 9.261

8.  Biphasic and dosage-dependent regulation of osteoclastogenesis by β-catenin.

Authors:  Wei Wei; Daniel Zeve; Jae Myoung Suh; Xueqian Wang; Yang Du; Joseph E Zerwekh; Paul C Dechow; Jonathan M Graff; Yihong Wan
Journal:  Mol Cell Biol       Date:  2011-08-29       Impact factor: 4.272

9.  Lipid Osteoclastokines Regulate Breast Cancer Bone Metastasis.

Authors:  Jing Y Krzeszinski; Adam G Schwaid; Wing Yin Cheng; Zixue Jin; Zachary R Gallegos; Alan Saghatelian; Yihong Wan
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

10.  HDAC7 inhibits osteoclastogenesis by reversing RANKL-triggered β-catenin switch.

Authors:  Zixue Jin; Wei Wei; Paul C Dechow; Yihong Wan
Journal:  Mol Endocrinol       Date:  2012-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.